CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

Use of Normal Tissue Complication Probability Models in the Clinic

Marks, L. B., Yorke, E. D., Jackson, A., Ten Haken, R. K., Constine, L. S., Eisbruch, A., Bentzen, S. M., Nam, J., & Deasy, J. O. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1754 · Cited by 1,826

Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study

Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653

Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection

Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629

Validation of a prediction tool for chemotherapy toxicity in older adults with cancer

Hurria, A., Mohile, S., Gajra, A., Klepin, H., Muss, H., Chapman, A., Feng, T., Smith, D., Sun, C.-L., De Glas, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.4327 · Cited by 598

Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study

Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467

Models for Delivering Survivorship Care

Oeffinger, K. C., & McCabe, M. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0474 · Cited by 485

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143974 · Cited by 173

Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424

Fisher, B. J., Hu, C., Macdonald, D. R., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner-Wasik, M., Bahary, J.-P., Liu, J., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.11.012 · Cited by 163

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Colen, R. R., Fujii, T., Bilen, M. A., Kotrotsou, A., Abrol, S., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0524-2 · Cited by 120

Central or Peripheral Catheters for Initial Venous Access of ICU Patients: A Randomized Controlled Trial

Ricard, J.-D., Salomon, L., Boyer, A., Thiery, G., Meybeck, A., Roy, C., Pasquet, B., Le Mière, E., & Dreyfuss, D. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31828a42c5 · Cited by 104

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3203 · Cited by 95

A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma

(2019) · doi:10.1016/j.aohep.2018.10.003 · Cited by 77

Late effects in adult survivors of childhood cancer: the need for life-long follow-up

Blaauwbroek, R., Groenier, K. H., Kamps, W. A., Meyboom-de Jong, B., & Postma, A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm336 · Cited by 73

Adverse events: the more you search, the more you find

Ioannidis, J. P. A., Mulrow, C. D., & Goodman, S. N. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00013 · Cited by 69

Non‐genetic risk factors and predicting efficacy for docetaxel–drug‐induced liver injury among metastatic breast cancer patients

Wang, Z., Liang, X., Yu, J., Zheng, X., Zhu, Y., Yan, Y., Dong, N., Di, L., Song, G., Zhou, X., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07131.x · Cited by 21

Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study

Xia, X., Jiang, W., Qi, W., Hong, B., & Zhao, W. (2020) · Oncology Research and Treatment · doi:10.1159/000510355 · Cited by 4